ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 830

Performance on Quality Measures in the RISE Registry and the Merit-Based Incentive Payment System (MIPS)

Jinoos Yazdany1, Tracy Johansson2, Rachel Myslinski3 and Salahuddin Kazi4, 1Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, 2Practice, Advocacy & Quality, American College of Rheumatology, Atlanta, GA, 3Governance & Ethics Specialist, Amer College of Rheumatology, Atlanta, GA, 4University of Texas Southwestern, Dallas, TX

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Payment, quality and registry

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Plenary Session I

Session Type: ACR Plenary Session

Session Time: 11:00AM-12:30PM

Background/Purpose: Under the new Medicare Access and CHIP Reauthorization Act (MACRA), the quality of care rheumatologists provide will have financial repercussions through the Merit Based Incentive Program (MIPS). MIPS will score providers across four domains: Quality, Clinical Practice Improvement, Advancing Care Information and Cost. In this study, we sought to evaluate performance on quality measures for practices participating in the Rheumatology Informatics System for Effectiveness (RISE) registry in the first quarter of 2017 and to develop a prototype dashboard for RISE to assist clinicians in understanding their MIPS performance.

Methods: The RISE informatics platform continuously collects data from the electronic health records (EHRs) of participating practices, allowing centralized aggregation and analysis of quality measures. Measures in the areas of rheumatoid arthritis, drug safety, preventive care and gout were examined. For the first quarter of 2017 (the initial period eligible for MIPS reporting), we calculated performance on quality measures, defined as the percentage of eligible patients receiving recommended care. We also developed a prototype dashboard for RISE that will display scores across the four MIPS domains to help clinicians track their performance over time.

Results: Data from 548,990 patients across 491 clinicians and 109 practices was examined. Most rheumatologists were in a group practice (72%); 26% were in solo practice and 2% part of a larger health system. Mean (SD) patient age was 59 (16) years, 75% were female, 21% were racial/ethnic minorities. Performance on measures varied significantly across practices (Table). For 2 of 5 measures for which the Medicare program has set national benchmarks, average performance of RISE practices exceeded targets in the first quarter of 2017. Quality measures that make up the MIPS quality domain were combined with simulated information for other MIPS domains to develop a MIPS dashboard prototype for RISE, displayed in the Figure.   

 

Conclusion:  We found significant variation in performance on quality measures in the first quarter of 2017 across RISE practices, with some practices having already achieved a very high level of performance. We anticipate that the MIPS dashboard prototype will go-live on the RISE user interface in late 2017 and will aid rheumatologists in proactively monitoring their MIPS score.

Table.  Performance on Quality Measures in the RISE Registry in 2017.

 

Electronic Quality

Measure (eCQM)

Measure denominator (N)

Average performance across patients

(%)

Pratice-level performance

(percentile)

CMS benchmark

50th

100th

Rheumatoid arthritis:

    Assessment of Disease Activity 

    Functional Status Assessment

    DMARD

95,662

95,662

95,662

46.2

45.6

91.0

43.6

42.6

93.9

83.8

85.9

95.7

Drug Safety

    TB screening pre-biologic

    1+ High-Risk Medication in Elderly*

    2+ High-Risk Medications in Elderly*

9,684

159,370

159,370

57.9

5.7

0.1

65.9

2.8

0

78.6

0

0

9.0

9.0

Preventive Care

   Tobacco screening and counseling

   BMI documentation, follow-up plan

   Blood pressure management

280,725

231,846

58,594

77.9

41.7

62.9

87.4

34.3

62.4

92.3

59.0

74.8

89.7

57.8

68.5

Gout

   Serum urate monitoring

   Serum urate target <6.8 mg/dL

   Serum urate lowering therapy

2,487

3,251

1,098

32.1

30.0

64.2

36.4

26.5

80

47.1

47.5

95.7

*Lower number indicates higher performance

Figure.  Prototype Merit Based Incentive Payment System (MIPS) Dashboard for the RISE registry.

 


Disclosure: J. Yazdany, None; T. Johansson, None; R. Myslinski, None; S. Kazi, None.

To cite this abstract in AMA style:

Yazdany J, Johansson T, Myslinski R, Kazi S. Performance on Quality Measures in the RISE Registry and the Merit-Based Incentive Payment System (MIPS) [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/performance-on-quality-measures-in-the-rise-registry-and-the-merit-based-incentive-payment-system-mips/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/performance-on-quality-measures-in-the-rise-registry-and-the-merit-based-incentive-payment-system-mips/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology